- Rolen v. Burroughs Wellcome Co., 856 S.W.2d 607, 609 (Tex. App.—Waco 1993, writ denied).
- Ibid. See also Alm v. Aluminum Co. Co., 717 S.W.2d 558, 591–592 (Tex. 1986); Reyes v. Wyeth Lab, 498 F.2d 1264, 1276 (5th Circuit 1974).
- Reyes, 498 F.2d 1276.
- In Re Norplant Contraceptive Products Liability Litigation, 165 F.3d 374, 379 (5th Circuit 1999).
- Gravis v. Parke-Davis & Co., 502 S.W.2d 863, 870 (Tex. App.—Corpus Christi 1973, writ ref nre).
- Reyes, 498 F.2d 1277.
- See Hurley v. Lederle Lab, 863 F.2d 1173, 1178–1179 (5th Circuit 1988).
- Wyeth-Ayerst Lab. Co. v. Medrano, 28 S.W.3d 87, 93 (Tex. App.—Texarkana 2000, no writ).
- See Hurley, 863 F.2d 1178–1179; Medrano, 28 S.W.3d 93.
- Alm, 717 S.W.2d 592, citing Bristol-Myers Co. v. Gonzales, 561 S.W.2d 801 (Tex. 1978); Crocker v. Winthrop Lab., 514 S.W.2d 492 (Tex. 1974).
- Gonzales, 561 S.W.2d 804.
- Rolen, 856 S.W.2d 609.
- See Stewart v. Janssen Pharmaceutica, Inc., 780 S.W.2d 910, 912 (Tex. pp.—El Paso 1989, writ denied); In Re Norplant, 955 et supp 710–711.
- See Fenrite v. Abbott Northwestern Hospital, 568 N.W.2d 535, 542 (Minn. App.), rev denied, November 18, 1997; Klein v. Biscup, 673 N.E.2d 225, 231 (Ohio App.), appeal denied, 667 N.E.2d 987 (Ohio 1996); 21 U.S.C. Section 906; 59 Fed. Reg. 59820, 59821 (FDA November 18, 1994).
- See, e.g., Ortho Pharmaceutical Corp. v. Cosprophar, Inc., 32 F.3d 690, 692; Washington Legal Foundation v. Kessler, 880 F. Supp. 26 (D.DC. 1995).
- Foreword to Physicians' Desk Reference, 55th ed. Montvale, NJ: Medical Economics, 2001.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 15, 2002 - Issue 1